Member Info for Frank09

He has more than 11000 followers on YouTube and more in social media - very smart guy. Don’t be distracted by his appearance

https://m.youtube.com/watch?feature=youtu.be&v=VhUjWy0Wk5M

Many Covid investors in the US watch and follow Dr. Yo. First sight he looks crazy, but he is really smart (MD, anesthesist

Yesterday they said 35 % reduction of plasma with the HIGHEST Titer !!!

How much such plasma with the „highest titer“ is available ?
Was is the reduction of mortality in plasma with AVERAGE titer ?

It is true that Trump said that. And indeed it is a disgrace that he said so!

Yes all three and 15 children I estimate

Wau, some of guys ask me a lot of personal questions. I am in BB in Germany on SNG (no interest there) that is why I am here. To the opposite: Relief Therapeutics - there is interest and good exchange in my German BB. And in the US I only talk about Cytodyn. Any further personal questions?

Yes, the market capitalization of SNG is still relatively small. And what I also like is: no hype in Germany or US with SNG.
On the other hand RLFTF is more advanced with their Phase II/III trial half done and having a drug that has already marketing authorisation in the US, UK and EU for other (acute) lung disease.

@ persimmon: that stem cell stock is MESO, not Relief Therapeutics.

@ sparkle. Same for me, I have a brother with idiopathic fibrosis (my mother died for that) and thus I am also interested for that reason in drugs against covid, including for the most severe cases. If you get the flu or covid on top of lung fibrosis you are at risk, I don't need to explain this. Also for that reason, I am interested in product pipelines wich can be also given per inhalator.

@ manifesto I am not gone. But somebody got nervous apparently for whatever reason and asked to delete the thread about "serious competitor". I am fine with that. As sparkle said, if it cannot be traded in the UK, it is of no use for the people here or only for those which a wider perspective without blinkers. I will come back and remind you when this competitor gets (soon) the marketing authorisation. I would be happy as much as you if SNG would getsit before.... you never know....

Maybe this one: phase 2 with a statistically significant difference to placebo on the endpoint „NEWS2“ (News2 was developed in England and seems to be a good clinical predictive endpoint): They applied for emergency approval in the UK, US, EU, and some other countries:

https://www.cytodyn.com/newsroom/press-releases/detail/462/cytodyn-requests-fast-track-approval-for-covid-19

https://www.cytodyn.com/newsroom/press-releases/detail/460/cytodyn-submits-its-top-line-report-from-its-phase-2

Yes, I know - but also the „small“ US Covid plays I was referring to have a pipeline with some more applications.

E.g Cytodyn - also great Phase II results on mild and moderate Covid patients (and half done with phase 2-3 in severe and critical Covid) have a number of additional trial and amazing phase III results against HIV.

Same for other US stocks - they all have more than only Covid. That makes it very difficult if not impossible to compare. But I agree nevertheless : Synairgen has a small market capitalization in comparison to these US stocks

US Covid plays (usually they have something more like SNG has with COPD), have a market capitalization of 1 - 1.5 billion . But these companies do not have yet such good results. Very difficult if not impossible to compare.

But just see the money US Warp spends for 1 vaccine producer just to speed up development (without guarantee that they gat something in return): 1-2 billions.

With an approved Covid drug which significantly reduced mortality (Synairgens Interferon b is not approved yet), for me the minimum should be about 2 bio. That is 4-5 of the today price and that should really be the absolute minimum (provided that also US approves)

Remdesivir does not work intravenously, why should it work via inhalation. Yes, I know that there was a secondary endpoint with a „statistical significant“ shorter hospital duration claimed by Gilead. What you normally do is: apply Bonferroni for multiple testing - and then this „result“ is negative. Apparently in pandemic situation, regulators are satisfied with a „may work“ instead of „proven that it works“. Very fine for me, but then Synairgen should get emergency approval right away. There results were truly statistically significant (and also clinically much more relevant) than the very questionable results for Remdesivir.

See the fatal cases, Remdesivir does not help at all, and so far not even confirmed from hospitals that the hospital duration after Remdesivir is shorter. This is fake like disinfectants for injections- just more seriously submitted by big Pharma and professionally but misleadingly reported by Gilead.

Not sure whether it was already discussed here. What do people here expect in the US ? Emergency use approval on the basis of the phase 2 results from July or do you expect that FDA and other drug authorities would request a confirmatory phase 3 study ?

Trump desperately wants and needs a covid drug. This Oleandrin has zero chance, but therefore the chance increase for Synairgen to get EUA in the US.

Correection: not „in their lung“, I meant „in other lung disease“ and in principle in all immunonsupressed people.

If we get an effect here then this effect is most likely also present in their lung. I am thinking about cystic fibrosis. Lung fibrosis, lung (or other cancers) or also immunosupressed patients - no reason why this effect (of present) would not be there in many other situations. The data against Covid are really impressive. If shown also in COPD patients - then this has much more potential then I originally thought. Thanks again Christoffer and John !

Thanks a lot, Cheistoffer, and also John! I am very well aware about it’s antiviral effect by boosting various cellular defense mechanism and increase resistance of surround cells against infection. I actually did my doctor (veterinary medicine) in virology. I did not get that link between COPD and the antiviral effect. I was wondering how Interferon could act here. But now it is clear to me and this is a sound hypothesis. Yes, obviously Interferon Beta could make sense here and have an effect. I did not check the study design - it may be difficult to show such effect in a Phase II study due to the limited statistical power of such trial. But let‘s see. If it was well designed, maybe something will be found which may result to a confirmatory phase III study.

Obviously - COPD has also huge potential. Here everybody is waiting for the study Phase II outcome. Can anybody here provide a link or source (peer-reviewed journal) about the proof of concept maybe from a phase I study or any other information from human data which indicate that Interferon Beta may work in COPD ? I am fully aware it is now up to the Phase II study to show some effect (any clinical relevant endpoint), but I am missing a bit the basis for that COPD optimism. Don‘t get me wrong, I have SNG (unfortunately only 2k), you may be well aware about existing human COPD data (if available). Or is this optimism entirely based on the mode of action of interferon b?

If the data on COPD are good, 15 Pounds per share would be about 2 Bio market capitalization - that is reasonable already without COVID!